Reported about 1 year ago
Du Huirong / Taipei reports on July 1, 2024, at 4:10 PM, Xun (6986) announced that its 'Mesenchymal Stem Cell Drug Production Technology' will be authorized to Collective Research Biomed with a total amount of 6 million US dollars (approximately 192 million New Taiwan dollars). The collaboration aims to develop exosomes derived from umbilical cord mesenchymal stem cells for various product developments in medical materials, new drugs, skincare, etc., focusing on wound healing treatment and medical beauty applications. Xun will receive an initial signing fee of 1.8 million US dollars in the first stage and could receive a total of 4.2 million US dollars in licensing fees in subsequent stages based on development progress, totaling 6 million US dollars. Xun indicates that this initial technology authorization marks a strong growth momentum as the company, in addition to mature CDMO/CMO services, ventures into exosome technology. Collective Research Biomed has a positive outlook on exosomes, with ongoing process research by Xun since 2022, focusing initially on wound healing and medical beauty applications.
Source: YAHOO